Ulinastatin shortens the length of ICU stay in critical patients with organ failure: A 7-year real-world study.

IF 2.6 4区 综合性期刊 Q2 MULTIDISCIPLINARY SCIENCES Science Progress Pub Date : 2024-07-01 DOI:10.1177/00368504241272696
Lixue Wu, Deduo Xu, Yanru Liu, Wenfang Li, Weiwei Jiang, Xia Tao, Jinyuan Zhang, Ze Yu, Fei Gao, Wansheng Chen, Zhaofen Lin, Yi Shan
{"title":"Ulinastatin shortens the length of ICU stay in critical patients with organ failure: A 7-year real-world study.","authors":"Lixue Wu, Deduo Xu, Yanru Liu, Wenfang Li, Weiwei Jiang, Xia Tao, Jinyuan Zhang, Ze Yu, Fei Gao, Wansheng Chen, Zhaofen Lin, Yi Shan","doi":"10.1177/00368504241272696","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ulinastatin has been applied in a series of diseases associated with inflammation but its clinical effects remain somewhat elusive.</p><p><strong>Objective: </strong>We aimed to investigate the potential effects of ulinastatin on organ failure patients admitted to the intensive care unit (ICU).</p><p><strong>Methods: </strong>This is a single-center retrospective study on organ failure patients from 2013 to 2019. Patients were divided into two groups according to using ulinastatin or not during hospitalization. Propensity score matching was applied to reduce bias. The outcomes of interest were 28-day all-cause mortality, length of ICU stay, and mechanical ventilation duration.</p><p><strong>Results: </strong>Of the 841 patients who fulfilled the entry criteria, 247 received ulinastatin. A propensity-matched cohort of 608 patients was created. No significant differences in 28-day mortality between the two groups. Sequential organ failure assessment (SOFA) was identified as the independent risk factor associated with mortality. In the subgroup with SOFA ≤ 10, patients received ulinastatin experienced significantly shorter time in ICU (10.0 d [interquartile range, IQR: 7.0∼20.0] vs 15.0 d [IQR: 7.0∼25.0]; <i>p </i>= .004) and on mechanical ventilation (222 h [IQR:114∼349] vs 251 h [IQR: 123∼499]; <i>P </i>= .01), but the 28-day mortality revealed no obvious difference (10.5% vs 9.4%; <i>p </i>= .74).</p><p><strong>Conclusion: </strong>Ulinastatin was beneficial in treating patients in ICU with organ failure, mainly by reducing the length of ICU stay and duration of mechanical ventilation.</p>","PeriodicalId":56061,"journal":{"name":"Science Progress","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11325468/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science Progress","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1177/00368504241272696","RegionNum":4,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Ulinastatin has been applied in a series of diseases associated with inflammation but its clinical effects remain somewhat elusive.

Objective: We aimed to investigate the potential effects of ulinastatin on organ failure patients admitted to the intensive care unit (ICU).

Methods: This is a single-center retrospective study on organ failure patients from 2013 to 2019. Patients were divided into two groups according to using ulinastatin or not during hospitalization. Propensity score matching was applied to reduce bias. The outcomes of interest were 28-day all-cause mortality, length of ICU stay, and mechanical ventilation duration.

Results: Of the 841 patients who fulfilled the entry criteria, 247 received ulinastatin. A propensity-matched cohort of 608 patients was created. No significant differences in 28-day mortality between the two groups. Sequential organ failure assessment (SOFA) was identified as the independent risk factor associated with mortality. In the subgroup with SOFA ≤ 10, patients received ulinastatin experienced significantly shorter time in ICU (10.0 d [interquartile range, IQR: 7.0∼20.0] vs 15.0 d [IQR: 7.0∼25.0]; p = .004) and on mechanical ventilation (222 h [IQR:114∼349] vs 251 h [IQR: 123∼499]; P = .01), but the 28-day mortality revealed no obvious difference (10.5% vs 9.4%; p = .74).

Conclusion: Ulinastatin was beneficial in treating patients in ICU with organ failure, mainly by reducing the length of ICU stay and duration of mechanical ventilation.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
乌利那他汀可缩短器官衰竭危重病人在重症监护室的住院时间:一项为期 7 年的真实世界研究。
背景:乌利那他汀已被应用于一系列与炎症相关的疾病中,但其临床效果仍令人难以捉摸:我们旨在研究乌利那他汀对重症监护室(ICU)收治的器官衰竭患者的潜在影响:这是一项针对2013年至2019年器官衰竭患者的单中心回顾性研究。根据住院期间是否使用乌利那他汀,将患者分为两组。为减少偏差,采用倾向评分匹配法。研究结果为28天全因死亡率、重症监护室住院时间和机械通气时间:结果:在符合入选标准的 841 名患者中,有 247 人接受了乌利那他汀治疗。608名患者组成了倾向匹配队列。两组患者的 28 天死亡率无明显差异。序贯器官衰竭评估(SOFA)被认为是与死亡率相关的独立风险因素。在 SOFA ≤ 10 的亚组中,接受乌利那他汀治疗的患者在重症监护室的住院时间明显缩短(10.0 d [四分位数间距,IQR:7.0∼20.0] vs 15.0 d [四分位数间距,IQR:7.0∼25.0];p = .结论:乌利那他汀对治疗心肌梗死有益,但在28天死亡率方面没有明显差异(10.5% vs 9.4%;P = .74):结论:乌利那他汀对治疗重症监护病房器官衰竭患者有益,主要是缩短了重症监护病房的住院时间和机械通气时间。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Science Progress
Science Progress Multidisciplinary-Multidisciplinary
CiteScore
3.80
自引率
0.00%
发文量
119
期刊介绍: Science Progress has for over 100 years been a highly regarded review publication in science, technology and medicine. Its objective is to excite the readers'' interest in areas with which they may not be fully familiar but which could facilitate their interest, or even activity, in a cognate field.
期刊最新文献
A voltage mode grounded capacitance multiplier with widely tunable gain for ultra-low cutoff frequency filter. Appropriate dose of tranexamic acid in the topical treatment of anterior epistaxis, 500 mg vs 1000 mg: A double-blind randomized controlled trial. Research status and prospect of flexible optimization design methodology of propeller CNC polishing machines. Sliding mode control with self-adaptive parameters of a 5-DOF hybrid robot. Spoofing attack recognition for GNSS-based train positioning using a BO-LightGBM method.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1